New hope for rare blood disorder patients as experimental drug enters trials
Disease control
Not yet recruiting
This early-stage trial tests a new drug called TGD001 in about 70 adults with acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) or other thrombotic microangiopathies (TMA). The goal is to check the drug's safety and how well it works at stopping dangero…
Phase: PHASE1, PHASE2 • Sponsor: TargED Biopharmaceuticals B.V. • Aim: Disease control
Last updated May 18, 2026 10:58 UTC